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Abstract: In Norway, genetically modified organisms (GMOs) are regulated through the Gene
Technology Act of 1993, which has received international attention for its inclusion of non-safety
considerations. In 2017, the Norwegian Biotechnology Advisory Board triggered a process to revise
the Act that included a public consultation and resulted in the “Proposal for relaxation.” Using
poststructuralist discourse analysis, we critically analyze the premises and processes through which
the proposal for relaxation was developed—including the public consultation—to understand the
range of stakeholder concerns and how these concerns shaped the final proposal. We find that the
proposal does not include all concerns equally. The Norwegian Biotechnology Advisory Board’s
privileging of technological matters and its preference for tier-based regulation skewed the proposal
in a way that reduced broader societal concerns to technological definitions and marginalized
discussion of the social, cultural, and ethical issues raised by new gene technologies. To prevent such
narrowing of stakeholder concerns in the future, we propose Latour’s model for political economy as
a tool to gauge the openness of consultations for biotechnology regulation.
Keywords: GMO regulation; non-safety considerations; consultation; perplexity; sustainability;
ethics; GMOs; genome editing
1. Introduction
In Norway, genetically modified organisms (GMOs) are regulated through the Gene
Technology Act of 1993 (GTA). The GTA is unusual in that it includes non-safety considera-
tions, demanding that GMO production and use take place in “an ethically justifiable and
socially acceptable manner” without harm to health and the environment [1] (Article 1). It
demonstrates similarities with Article 26 of the Cartagena Protocol on Biosafety and the
EU’s Directive on GMOs (EU 2015/412), which allows member states to restrict GMOs
“based on grounds related to socio-economic impacts” cf. [2,3]. Although Norway is not a
part of the European Union (EU), EU Directive 2001/18/EC [4] is applicable to Norway
due to Norway’s obligations through the European Economic Area (EEA) agreement. This
implies that an approval of a GMO in the EU automatically leads to an approval in Norway,
unless it is prohibited. As of June 2021, Norwegian authorities have approved five GM
carnations with changed color, whereas 13 GMO applications approved in the EU have
been forbidden in Norway (10 GM plants, two vaccines, and one test kit that contains GM
microorganisms) [5].
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To aid implementation of the GTA, the Norwegian Biotechnology Advisory Board
(NBAB) has established detailed guidance documents for the assessment of two of the
non-safety considerations [6–9]. The societal utility criterion in the GTA is only relevant
for impacts of the product within Norway, whereas the sustainability criterion may take
into consideration factors that evolve over the longer term or affect global developments.
In 2017 the Norwegian government prohibited a GM maize on ethical grounds. This
prohibition initiated the development of a guide for ethical assessments [10], which the
Ministry of Climate and Environment is currently evaluating.
Despite such work to concretize non-safety assessments, there still exists a widespread
conception that non-safety assessments place additional regulatory burdens on GMO
regulation and present a barrier to the technology’s development [11]. There is further
disagreement on what constitutes non-safety considerations and the scope of such as-
sessments [3,12,13]. In Norway, experience with current regulation has caused concern
among biotech and breeding companies that the GTA’s non-safety assessments could be
used to ban any GM product from the Norwegian market. Recent surveys reveal a slight
majority of the Norwegian public to believe GMOs will have negative effects on natural
ecosystems and human and animal health, and to place more emphasis on non-safety
assessments [14–16]. (These findings are presented in survey reports that are issued by
scientific environments, but that have not been submitted to scientific peer review pro-
cesses. Accordingly, charges of bias have been made against them [17–20] and their results
must be used with precaution.) In line with the findings of Menozzi et al. [21], broader
public engagement appears to evoke a broader set of concerns, and effective forms of public
engagement may be used to identify research needs on the socio-economic effects of the
possible development and use of new GMOs.
NBAB is an independent body of government-appointed experts with responsibility
to assess GMO applications based on their impact on sustainability, societal utility, or
ethics; advise the Ministry of Climate and Environment on whether to approve or dismiss
such applications; and facilitate knowledge dissemination and public debate on topics it
deems important [22,23]. In 2017, NBAB published a report entitled “The Gene Technology
Act-Invitation to public debate” [22,24]. The report invited public comment on its proposal
to relax the GTA in order to reduce the regulatory burden on applicants and accommodate
advances in genome editing. NBAB argued that the GTA had not kept pace with the
emerging scientific developments in gene technology. For example, the relative simplicity
and low cost of using emerging gene technologies meant an increase in applications
for GMO-product approvals was likely and the GTA needed to provide a stable, easily
operationalized, and predictable framework for the corresponding assessments. The
inclusion of non-safety considerations posed a potential barrier to this goal.
The public consultation took place between December 2017 and May 2018 and gar-
nered 46 Norwegian submissions. In light of these public submissions, NBAB published the
revised “Proposal for relaxation of Norwegian regulations for deliberate release of geneti-
cally modified organisms (GMO), with applicability also for EU legislation” in December
2018 [25]. The proposal outlined a differentiated regulatory system based on biological
categorizations and maintained that non-safety assessments should remain. In response, in
2020, the Ministry of Climate and Environment appointed a committee tasked to develop a
white paper on GMO regulation before the end of 2022.
NBAB’s proposed “Norwegian model” is internationally recognized [26,27] and con-
sidered a possible model for the EU, as it strikes a balance between harnessing the potential
of gene technologies and accommodating public and stakeholder concerns [11]. Given the
prominence of Norway’s approach to the treatment of non-safety assessments in biotech-
nology regulation, there is a need to investigate this potential regulatory shift. Importantly,
there is a need to understand how non-safety considerations fare under pressure to relax
regulations and how public and stakeholder input shaped the relaxation proposal. We
address this need through a poststructuralist (Foucauldian) discourse analysis to investi-
gate (1) NBAB’s framing of the problem and the consultation, (2) public and stakeholder
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concerns raised through the consultation, and (3) NBAB’s integration of these concerns in
its final proposal.
We outline the ways in which NBAB’s problem framing shaped the public consulta-
tion and show how some stakeholders shaped the final proposal more than others. Our
humanities-based study seeks to contribute to cross-disciplinary dialogue by revealing
the concepts and narratives upon which current problem definitions depend, and how
they change according to the different actors’ vocational, political, and ideological po-
sitions within the field of debate. Furthermore, we apply Latour’s model for political
ecology [28] as a measure of how well NBAB succeeds in engaging the public in a broad
and inclusive consultation on the development and use of gene technologies. This gives
us an indication of the way these technologies support or challenge current non-safety
assessments. We argue that if gene technologies are to address sustainability challenges, as
their proponents claim, broader and more inclusive discussions are needed that include
biological and ecological parts of (nature–culture) collectives as essential to both safety and
non-safety considerations.
Latour’s Model for Political Ecology
The scientific facts of gene technology have shaped public policy in ways that favor
permissive regulatory regimes and the prerogative of geneticists to “push research to
its limits” until it challenges technically defined limits of risk to human health or the
environment [29] (p. 26). Historically, this framing of scientific risk has subordinated the
social and ethical aspects of gene technology to scientific issues, leaving them “a marginal
role in the development of governance structures” [30] (p. 781); cf. [31–33]. The emergence
of a high-profile ethical agenda for GMOs in Europe has been unable to improve this
situation because it relies on deontological or utilitarian approaches that presuppose that
harms and benefits can be readily identified, and that conceives of ethical judgements in
terms of individual convictions based on emotions [33]. The public is left with the choice
“either to recognize and accept what the scientists [say] about risks, or to be defined as
irrational and emotive” [33] (p. 455). According to Wynne [33], this causes a situation in
which public concerns involving a combination of intellectual and ethical judgements on
scientific knowledge and forms of ownership, including the quality of scientific institutions
and their willingness to discuss the limitations of their own knowledge culture, are severely
underestimated. In this manner, a clear separation between “scientific facts” and “ethical
concerns”—often supported by derogatory representations of the intellectual capacities
of the public—serves to protect scientific-based policy cultures from self-reflexivity [33].
Non-governmental organizations (NGOs) and other actors concerned with the broader
socio-cultural and ethical consequences of gene technology suspect their concerns are
neglected [30], which hampers deliberation on the regulation and use of the technology.
Latour’s model of political ecology, outlined in Politics of Nature [28], is designed
specifically to deal with tensions between facts and values and/or experts and lay publics.
Latour argues “it is impossible to begin to ask the moral question after the states of the
world have been defined,” and offers a model in which “the question of what ought to be
is not a moment in the process; rather, it is coextensive with the entire process” [28] (p. 125).
Instead of leaving it up to the scientist to decide what constitutes the common world and
up to politicians and philosophers to determine what a good world looks like, Latour’s
political–ecological collective outlines a model in which multiple actors with specific and
valuable expertise partake in the construction of a good common world [28] (p. 93).
Central to Latour’s model for political ecology is a re-conceptualization of traditional
fact–value distinctions and of what it means to properly take into account all viewpoints
and arguments in deliberations on what constitutes a good common world. Latour specifies
that the power of taking into account consists of two processes: consultation and perplexity.
Perplexity has to do with the processes through which natural facts are constructed. It
denotes a state of bewilderment and momentary incomprehension experienced as scientists
(and other producers of knowledge) encounter new entities that make an impact on
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the world yet exist beyond what scientific instruments can measure; what theories and
paradigms can make sense of and predict. These are “entities or phenomena presenting
themselves initially in the first form, in the laboratory, on the research front, in the garb of
beings of uncertain status that demand to be taken into account” [28] (p. 103). Latour names
these entities propositions because of the way they propose their candidacy for existence
in a common world [28] (p. 104). Propositions’ key feature is the way they momentarily
challenge established (and materially supported) knowledge production systems and leave
those who are discussing them “perplexed” [28] (p. 104).
The function of consultation is to determine “what trials are appropriate to pass
judgment on the existence, the importance, and the intention of a proposition” [28] (p. 239).
Importantly, the process of consultation applies to non-humans as well as humans, and
involves carefully putting together the best possible jury capable of judging the effect of
each proposition on the already existing collective of humans and nonhumans. Drawing
on politicians’ expertise in making all voices heard, consultation, in Latour’s reformulation,
“does not have the ordinary meaning of [debating] an answer to an already-formulated
question,” but implies active “participation in the reformulation of the problem through a
search for reliable witnesses” [28] (p. 239).
Latour’s way of combining perplexity and consultation in the proper processes of
taking something into account (what we may call deliberation) does two important things.
First, it acknowledges the processes of construction through which natural “facts” be-
come established and the initial states of indeterminacy and ignorance these processes
often originate in. Second, it associates the processes of knowledge construction with
the processes of consultation through which appropriate trials and reliable witnesses are
sought. Latour’s reconceptualization of the political–ecological collective in this way opens
up for different and more participatory processes of knowledge construction in which a
range of actors—providing a range of different forms of knowledge—are involved. In the
case of GMOs, not only molecular scientists and producers of gene technology, but all
kinds of biologists, ecologists, farmers, breeders and other producers of the technology,
consumers, NGOs, and concerned citizens contribute to the construction of knowledge of
what new GMOs are and may become. Democratic inclusion becomes a matter not only of
the ability to participate in political processes (making all voices heard), but also a matter
of allowing different voices to participate in the official production of what ends up as
scientific–cultural matters of fact [28] (pp. 114, 128, 244). Latour’s model resembles other
models for democratic and open forms of public consultation (or engagement) seeking
to establish better ways of co-producing knowledge [34,35], but goes beyond these by
including propositions and those who articulate their candidacy into the conceptualization
of consultation [28] (pp. 86, 237).
In this way, Latour’s model highlights how the establishment of matters of fact are
intricately associated with questions of who is accepted as a witness and allowed to engage
in framing the discussion questions in debates on how to construct a good common world.
Openness to perplexity becomes a question of value. Only by allowing this openness to
remain—to take as much time and include as many propositions and voices as possible—
can the production of knowledge transcend the enclosed spaces of science and —in the
case of gene technology—allow other questions to be formulated than whether or not the
GMO produced is “safe enough” for application from the perspective of molecular biology.
Processes of taking into account are, moreover, acknowledged as fundamental to
what we traditionally conceive of as discussions of value: the hierarchization of different
and possibly conflicting ethical standards/principles that determines the place of new
propositions within already established value systems [28] (p. 109). Thus, Latour’s model
shows great promise in clarifying that the framing of questions treated in considerations of
new natural–technological propositions like GMOs and emerging genome edited organisms
already involves the establishment of values—also when the framing appears to be purely
scientific. Moreover, it highlights that neglecting perplexity is a way to partake in this
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value-laden framing, even in cases when this neglect consists primarily of not making full
use of the potential and diversity of the sciences.
Latour’s call for a broader integration of ethical and social concerns emerges at the
core of the recent European Group on Ethics in Science and New Technologies’ Opinion on
the “Ethics of Genome Editing” [36], which specifically deals with the complex issue of
how to evaluate the role and regulate the use of genome editing in a good, common world.
By overtly questioning the “safe enough” narrative of molecular biology, in which ethics
tends to become a secondary, justifying “add-on” to otherwise scientific assessments of
gene technology and its products, the opinion challenges “the tendency of scientific and
technological developments to mould governance and ethics” [36] (p. 21). Highlighting
such real and experienced effects of the “safe enough” framing, it signals the relevance
and possible impact of Latour’s model of political ecology at this particular point in
time. Here, both Norway and the EU are revisiting their GMO regulations in light of
recent scientific developments and increasing pressures to coordinate national and regional
regulations to allow global trade in GMO products [25,37]. In this context, the inclusiveness
and form of consultation is key, and contended issues are how current or future GMO
regulations may support long-term political goals and strategies for more sustainable food
systems—as manifested globally in the UN Sustainable Development Goals and FAO’s
Sustainability Assessment of Food and Agriculture Systems [38,39], in the European Green
Deal [40] and the EU Commission’s Farm to Fork Strategy [41]. In these policy documents,
socio-economic (and a limited range of ethical) concerns inform the understanding of
sustainability, and hence the possible contribution of new gene technologies to sustainable
development.
2. Materials and Methods
We designed a three-step method of poststructuralist discourse analysis to analyze
(1) how NBAB’s invitation framed the public debate, (2) concerns raised by stakeholders
and public in the debate, and (3) how these concerns were represented in the final docu-
ment. Our analysis focused on three publicly available documents: (D1) NBAB’s 2017 “The
Gene Technology Act—Invitation to public debate” [22,24], (D2) the written responses from
46 Norwegian respondents [42], and (D3) NBAB’s 2018 “Proposal for relaxation of Norwe-
gian regulations for deliberate release of genetically modified organisms (GMO)” [25] (see
Table A1 in the Appendix A). D1 and D3 are published in both Norwegian and English.
D2 is available in Norwegian only, and in order to perform a nuanced investigation of
respondents’ application and possible reworking of concepts and categories presented in
D1, we analyzed the original Norwegian documents. For the reader’s convenience, refer-
ences to D1 [22,24] and D3 [25,43] refer to the English versions [22,25]. We excluded the
report(s)’ treatment of the issue of labeling and traceability, as it would require extensive
and different discussions on the effect of framing the public in terms of consumers rather
than citizens. To be able to draw conclusions on the state of the Norwegian debate, we only
included submissions from Norwegian institutions, organizations, and individuals, and
hence excluded the single international submission, which was from the German Federal
Office of Consumer Protection and Food Safety. Finally, we note that NBAB organized a se-
ries of debate meetings in seven Norwegian cities, as well as one in Copenhagen, Denmark,
in order to stimulate public engagement and encourage written responses to the hearing. A
video recording of one of these meetings is published on NBAB’s webpage (https://www.
bioteknologiradet.no/2018/08/vi-stroymer-fra-gmo-mote-i-arendal-kl-12-30/, accessed
on 6 July 2021), but as no comprehensive visual or textual record of this meeting series is
publicly accessible, they are not included in our analysis.
Step one of our method focuses exclusively on D1, uncovering the narrative framing
of the issues addressed and revealing the underlying problem representation of NBAB’s
invitation. Step two focuses exclusively on D2, drawing on poststructuralist policy analy-
sis [44,45] to uncover the way perceived matters of concern support underlying understand-
ings of the problem(s) associated with gene technology and with the GTA in its current
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form. Such problem understandings determine respondents’ concerns regarding NBAB’s
proposal (see Table 1, p. 10). We use the Latourean concept of perplexity to measure and
describe the respondents’ recognition of yet undiscovered or unknown aspects of genetic
phenomena—including their networks of interconnections with other propositions and/or
phenomena and how these open up for uncertainties beyond those defined by scientific risk
assessment frameworks in GMO regulations. Consultation becomes a measure of the range
of actors—human and nonhuman—considered to be relevant in ongoing discussions on
gene technology. Respondents’ openness to value judgements provides an estimate of their
relative acceptance or resistance towards value-based non-safety assessment requirements.
Finally, step three compares the results from step two with our analysis of D3 to understand
which issues of public concern are reflected in NBAB’s final proposal.
In applying Latour’s idealized model of public consultation as an analytical framework
to evaluate the performance of NBAB in initiating, conducting, and reporting on the public
consultation, we develop a clearer understanding of the degree to which the consultation
was open, inclusive, and responsive. More broadly, this experimental application of
Latour’s framework on the case under study aims to promote an innovative and practical
perspective on fundamental issues of knowledge construction and the relationship between
facts and values that have hampered GMO debates for decades.
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Table 1. Major findings in the hearing responses.
Matters of Concern for
Biotechnology Regulation
Perception of the Problem(s) of Gene
Technology and/or the Current GTA
Concerns regarding NBAB’s












Strict regulation blocks development,
not adjusted to technological
development
GTA strict and outdated; not rigged for
the future
Effect on relationships with EU
regulations is unclear
Knowledge base for pre-defined
categories is limited








degradation and CRISPR technology
cause need to think in new ways – the
rules of the game change
GTA neutral framework
Effect on relationships with EU
regulations is unclear
Knowledge base for pre-defined
categories is limited
scientific knowledge gaps
environmental effects exclusive rather limited









New technologies offer new
possibilities and new challenges.
Suggested revisions will limit freedom
of action




Increases pressures on ecosystems
Knowledge base for pre-defined
categories is limited












Suggested revisions threaten the
precautionary principle, democratic
processes and the trust between
producers and consumers, lawmakers
and the public
GTA well-functioning and flexible
Disregards scientific knowledge
gaps/disagreements




Is detrimental to networks of trust









Suggested revisions threaten the
precautionary principle, democratic
processes and relationships with the
EU. Will lead to increased pressures
on already strained ecosystems
GTA well-functioning and flexible
Challenges existing relationships
with EU regulations
Increases pressures on ecosystems
Disregards scientific knowledge
gaps/disagreements
Knowledge base for pre-defined
categories is limited
Undermines sense of nature as
common good
scientific knowledge gaps inclusive high (implicitly)
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Table 1. Cont.
Matters of Concern for
Biotechnology Regulation
Perception of the Problem(s) of Gene
Technology and/or the Current GTA
Concerns regarding NBAB’s













The GTA is ‘out of sync’ with
regulatory frameworks in other




and sense of insecurity
GTA outdated (or neutral); lacks clear
definitions; not rigged for the future
Effect on relationships with EU
regulations is unclear
Knowledge base for pre-defined
categories is limited








Strict regulation hinders sustainable
development; Subjective non-risk
criteria may block any product: GTA
strict and old;
Suggested revisions are too simplified:
lack analyses of experiences with the
current GTA, of unintended and
detrimental effects on democracy and
relationships of trust, and of increased
pressures on natural environments
and ecosystems: GTA well-functioning
Increases pressures on ecosystems
Disregards scientific knowledge
gaps/disagreements
Knowledge base for pre-defined
categories is limited















Subjective non-risk criteria undermine
objective, scientific risk assessments,
cause unpredictability and may be
used to block any product; GTA
hinders development: GTA strict and
unpredictable; discriminatory
Suggested revisions, and resulting
approval of GMOs in agriculture,
maintain a socio-economic status quo
detrimental to the natural
environment: GTA well-functioning








Is detrimental to networks of trust
Undermines sense of nature as
common good
varied varied varied
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Table 1. Cont.
Matters of Concern for
Biotechnology Regulation
Perception of the Problem(s) of Gene
Technology and/or the Current GTA
Concerns regarding NBAB’s




















Gene technology is dominated by
large international corporations that
do not have people’s best interest in
mind; Systemic pressures against
God’s creation are increasing and
alternative solutions are necessary to
protect its most vulnerable members;
Scientific uncertainty and ignorance
are easily under-communicated; Being
against gene technology is not a
legitimate option: GTA well-functioning
Challenges relationships with
EU regulations
Increases pressures on ecosystems
Disregards scientific knowledge
gaps/disagreements























The GTA is too strict and unpredictable
because founded in politics and social
constructions, and it hinders
development; Non-safety criteria are
flawed and should be removed: GTA
strict and unpredictable; unnecessary
Strong business interests, financing of
research, research methods and choice
of evidence provide a skewed image
of reality; Gene technology alters time
perspective of evolution and may
disrupt fine-tuned ecological balances;
Reductionist scientific thinking not
equipped to handle the complexities
of gene modification: GTA
well-functioning and future oriented;
protects research and consumer interests
Increases pressures on ecosystems
(version of)
Knowledge base for pre-defined
categories is limited
Is detrimental to networks of trust
(version of)
varied varied varied
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3. Results
This section is divided into three subsections that correspond to our three-step analysis.
The first presents findings from the analysis of D1 and reveals NBAB’s framing of the public
consultation. The second presents the findings from our analysis of D2, the consultation
submissions. Finally, Section 3 reveals the degree to which public concerns were reflected
in D3, NBAB’s final proposal.
3.1. NBAB’s Framing of the Debate (D1)
Our analysis of D1 reveals how NBAB’s draft proposal to relax the Gene Technology
Act frames (a) GMOs as an economic opportunity to be harnessed, (b) naturalness as a
concept that justifies regulatory relaxation, (c) genome editing techniques as beyond ethical
consideration, and (d) ethical issues as separate from practical work with gene technology.
NBAB’s framing relies heavily on two proposed models for regulatory relaxation on
which consultation participants were asked to comment. Model 1 (D1, p. 27) is NBAB’s
preferred model and is the more radical, designed to reduce long and unpredictable
assessment procedures. It relies on ranking the genetic changes into three levels: Level 1
involves changes that could occur naturally or through conventional breeding methods,
level 2 includes organisms with species-specific genetic changes, and level 3 refers to
organisms that include cross-species genetic changes or involve synthetically designed
DNA-sequences. In Model 1, many genome edited organisms would undergo simplified
impact assessments. Only products on Level 3 would be subject to the assessments and
approvals of the current system, which includes public consultation.
Model 2 is less radical in the sense that it maintains the original process-based and
precautionary approach to regulation. Here, the non-safety assessment precedes scientific
risk assessment. A differentiation is made between products with strong (level 1), moderate
(level 2), and poor (level 3) ethical justification (D1, p. 34). Applications at level 1 may
undergo simplified risk assessments, whereas those on level 2 follow existing regulatory
processes. Applications for GMOs categorized in level 3 will be rejected, making costly and
time-consuming procedures of risk assessment unnecessary. Model 2 specifies that not only
the genetic changes made to an organism, but also the process of modification, its associated
uncertainties, and available alternatives are aspects relevant to ethical justifiability. Ethics
is understood comprehensively as “concerned not only with articulating and avoiding
what is bad, but also understanding and promoting what is good” (D1, p. 34).
3.1.1. GMOs as an Economic Opportunity to Be Harnessed
The observation that Model 1 is NBAB’s preferred model is based on its alignment
with the basic framing of the consultation (D1). NBAB’s aim is to “develop appropriate
and robust regulatory frameworks that facilitate the harnessing of the potential of gene
technology, while also avoiding harm to health and the environment, and promoting
sustainability, societal benefit and ethics” (D1, p. 3). Presuming that the bioeconomy will
rely on technological innovation, NBAB imagines that the GTA “will define the framework
for the use of gene technology in the future bioeconomy, and positive and negative conse-
quences of the different alternative forms of regulations should [therefore] be weighted
against each other” (D1, p. 6 [sic.]). It points to the negative consequences of process-based
regulation, citing studies showing that the average EU GMO application assessment took
nearly five years and cost producers between USD 10–30 million (D1, p. 26). This frames
the underlying problem of current GMO regulation as one that hinders gene technology
research and economic development. In presenting GMOs and genome edited organisms
as an economic opportunity to be harnessed, NBAB implies that the GTA blocks the de-
velopment of potentially sustainable, socially beneficial, and ethically sound products in
Norway. What allows this blockage is the GTA’s process-based approach to regulation,
which through the precautionary principle actuates non-safety assessment criteria that
can be used to overrule scientific risk assessments. NBAB’s position reflects that of gene
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technology developers and supporters who have long argued that the GTA’s process-based
approach is old fashioned and in need of revision.
3.1.2. Naturalness Justifies Regulatory Relaxation
According to the GTA, a GM organism is “a microorganism, plant or animal in
which the genetic material has been altered by means of gene or cell technology” [1]
(Article 4b). This is different from the EU Directive’s definition of a GMO as an organism
“in which the genetic material has been altered in a way that does not occur through
natural reproduction and/or natural recombination” [4] (Article 2.2). NBAB nevertheless
frames GMOs on a scale of “naturalness” to allow some to bypass regulatory scrutiny.
Claiming that Norwegian legislation rests on a distinction between what can and cannot
occur naturally/in nature, it promotes two arguments that rest on the fuzziness of this
concept. The first is that genetic modifications utilizing the naturally occurring processes
of making mutations may be considered “natural” (D1, p. 12). The second relies on
conceptualizations of naturalness as a continuum of degrees (D1, p. 12) to argue for a
graded regulatory regime that differentiates between GMOs identified as more or less
close to “the natural.” In support of this, NBAB refers to the EU’s report from May 2017,
“New techniques in agricultural biotechnology,” which concludes that the “variety and
versatility” of new techniques of genome editing means that grouping them together “may
not be optimal for scientific or other reasons” [46] (p. 17), (D1, p. 14). NBAB’s discussion
of naturalness thus establishes a parallel between the regulatory tiers of Model 1 and
degrees of property-based forms of naturalness. It does this by evoking naturalness as a
foundation for legislation, although this is not the case in Norway (unlike in the EU), and
through selective use of theoretical work on the concept of naturalness [47]. Significantly,
this selectivity involves ignoring discussions of history- and relation-based dimensions of
naturalness present in NBAB’s source [47], which are of high relevance to the ethical aspect
of the GMO debate [36].
3.1.3. Genome Editing Techniques as beyond Ethical Consideration
The way in which genome editing is framed in D1, as a controllable form of molecular
biology, weakens the argument of non-safety considerations and lends further support
for Model 1. For example, NBAB presents background information on different gene
technologies in a fact box that downplays the distinction between conventional forms
of breeding and old forms of gene technology (D1, p. 8–9). “Conventional” breeding
techniques involving the modification of genomes yet exempted from regulation (muta-
genesis, triploidization, and cell fusion) are presented in ways that emphasize human
intervention in living cells using radiation, high pressure and temperatures, enzymes, and
other chemicals. Similarly, descriptions of older, “classic” forms of gene modification reveal
the use of virus and bacteria, chemicals, electricity, microinjections, or gene cannons on
living cells. In contrast, newer forms of genome editing methods are framed strictly at the
molecular level. Indicating that only target genes are affected, NBAB presents a classic
molecular–biological framing that purifies the new techniques of gene technology ([32]
(p. 135); [48] (p. 10)) by presenting its scientific facts as separate from human agency and
stresses its precision and predictability. Potentially ethically challenging forms of human
intrusion slip away, preparing the ground for neglecting the processes of manipulation
and treating the products of this technology like any other manufactured product. The
conspicuous lack of corresponding fact representations of unintended and/or potentially
harmful effects of the presented genome editing methods serve the same function. In this
manner the invitational report’s (D1) presentation of the facts of gene technology subtly
contests the GTA’s process-oriented definition of new, genome edited GMOs.
3.1.4. Ethics as Unconnected or Secondary
The invitational report (D1) at several instances declares NBAB’s unanimous agree-
ment to maintain the principle of assessment of criteria for sustainability, societal benefit,
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and ethics (D1, pp. 4, 41, 42). This open support of non-safety considerations is never-
theless undermined by the report’s abstract representation of ethical approaches. The
report presents in some detail different ethical positions that may form the basis of ethical
assessments (D1, p. 18). However, no indication is given of what difference it would
make to apply the principles of care ethics rather than a consequentialist framework on the
assessment of GMOs. Unlike arguments in favor of gene technology, ethical positions and
arguments are not connected to real-life examples, and readers learn nothing about the
kind of ethical challenges researchers and producers face as they work towards products
like hornless cattle or sterilized salmon for aquaculture: challenges of balancing benefits
with drawbacks and of assessing in what ways and for whom the methods and changes
involved may have ethical consequences. A fact box lists examples of traits under devel-
opment (D1, p. 17), but the categories listed are all positive and the connection between
“good” products and positive ethical judgement is hinted at rather than openly asserted
and critically discussed. This tacit positive ethical framing of the new gene technologies
arguably works in support of the report’s economic framing of the issue of GMO regulation
and hints of a need to rework the possible impact of the non-safety assessment criteria
based on economic and scientific realities.
Overall, NBAB’s draft report and call for public consultation (D1) frames the case
for regulatory relaxation of genome edited organisms by emphasizing their economic
potential, foregrounding their naturalness, presenting genome editing techniques within
a paradigm of molecular biology highlighting their pure scientificity and precision, and
maintaining a separation between (abstract) ethical positions and the practical utilization
and consequences of the new technologies. The chapter entitled “Sustainability, societal
benefit and ethics—important considerations” begins not with an explanation of how and
why these considerations are important but with a discussion of the societal consequences
of different regulatory systems that highlights how “disproportionately strict” regulatory
systems make product development “unpredictable, time consuming and expensive” and
restrain the competitive abilities of Norwegian actors in international markets (D1, p. 16).
It moreover suggests that “product traits” rather than “production process” are what
determine the sustainability, societal benefit, and ethics of GMOs (D1, p. 16). The last
chapter of NBAB’s invitational report, entitled “Sustainability, societal utility and ethics:
How much is sufficient?” is less than a page (D1, p. 41). Maintaining that “one might
question whether it is necessary to require GMO products to having to contribute to
increased sustainability and societal benefit, since other products are not subject to such
requirements for approval,” NBAB’s report both in form and content suggests that a little
ethics is enough (D1, p. 41 [sic.]).
3.2. Major Trends in Responses to the Hearing (D2)
This section presents the results of the discourse analyses of the consultation submis-
sions (D2) in step two. Table 1 summarizes these findings and is organized around three
substantive clusters of actors: (a) business and industry, (b) agricultural and environmental
organizations, (c) scientific and research institutions (including responses submitted by
academics independently of their institutional affiliations [see Table A1]), and two smaller
clusters—(d) other interests/organizations, and (e) individual responses. Below, we discuss
these findings for the three main actor clusters. We list responses from the two smaller
clusters in Table 1 only.
3.2.1. Business and Industry Actors (8 of 46 Responses)
The perception of what constitutes the underlying problem concerning the regulation
of gene technology varies according to the position and power of the respondents. Umbrella
organizations representing Norwegian business and industry support NBAB’s problem
framing, arguing that the GTA restricts their access to international markets and that they
are falling behind in comparison to international competitors.
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Two actors in this group highlight Norway’s competitive advantage based on “its
restrictive use of antibiotics and pesticides, its focus on animal welfare, health and fertility,”
and its GMO-free production lines. However, as more countries make use of CRISPR tech-
nology, they believe power relationships built on competence will shift, and the possibility
to maintain the competitive advantage built on successful and systematic long-term work
in traditional breeding and food production will disappear. The underlying problem is the
new competitive premises of the market generated by the genome editing technologies.
They nevertheless adhere to the views of the rest of the group in perceiving a revision of
the GTA necessary to solve the problem.
Many actors in business and industry believe gene technology can address environ-
mental problems; however, they focus on economic sustainability such as improvements
to production processes to reduce waste and better animal health. In framing genome
editing as an enabling technology to propel economic development and environmental
sustainability, such actors argue for speeding up research and innovation and support
legislative revisions that make this possible. A technologically uninformed and prejudiced
public, giving GMOs a “sordid reputation” and opposing “knowledge-based” decisions re-
garding commercial use, emerges as a significant risk factor. Unsurprisingly, these business
and industry actors are not supportive of broad democratic involvement. Instead, they
imagine the processes of consultation as exclusive both in terms of forms of knowledge
and actors involved.
3.2.2. Agricultural and Environmental Organizations (9 of 46 Responses)
Agricultural umbrella organizations call for a better balance between international
competitiveness and the need to maintain a precautionary approach. Like other agricul-
tural organizations, they find NBAB’s relaxation proposal problematic and worry about
the well-being of small Norwegian actors if deregulation opens up competition from an
international market of GMOs. Norwegian legislation is interpreted as offering the freedom
to refrain from using gene technology in food production. This freedom is unique in an
international context and relies on the GTA’s precautionary approach and inclusion of
non-safety assessment criteria, through which Norway has negotiated an exemption from
EU legislation. Agricultural organizations accordingly emphasize the already existing
flexibilities of the current legislative framework.
Agricultural and environmental organizations alike are critical of Model 1 because
the removal of public consultations for level-1 and -2 applications threatens carefully
built systems of trust between producers, consumers, and authorities, which remain
important for democratic as well as economic reasons. They support consultation that
includes a broader range of (human and nonhuman) actors than business and industry
organizations and raise concerns that regulatory relaxation may threaten both democracy
and nature. These organizations share an environmental concern about the “balance” of
natural ecosystems and how GMOs might impact the structural dynamics of complex, open
systems. The behavior of such systems is marked by radical forms of uncertainty [49,50]
and evokes perplexities. Agricultural and environmental organizations raise concerns
that regulatory relaxation may result in a significant increase in approved applications for
commercial use, thereby placing more pressure on already stressed ecosystems. Uncertainty
about the impacts of new genome editing techniques means that these new risks may be
larger than the risks associated with traditional GMOs. They take issue with NBAB’s claim
that small genetic changes cause small (genetic) effects and argue the knowledge needed to
establish the biologically based categories on which Model 1 rests does not exist. The sense
of perplexity these organizations evoke is thus more pronounced than for organizations
representing industrial interests. Fearing that regulatory relaxation through legislative
change will be an irreversible process of cascadic (and negative) social, economic, legal,
and ecological consequences, these actors implicitly seek the protection of both nature and
the law.
Sustainability 2021, 13, 7643 14 of 25
3.2.3. Scientific and Research Institutions (17 of 46 Responses)
Scientific environments using gene technology for research and innovation purposes,
as well as a few university bioscience environments, follow NBAB in identifying a strict
and outmoded GTA as the problem to be tackled. Other scientific environments point
out biological/ecological and bureaucratic complexities that challenge NBAB’s proposal
and indicate a need for openness towards risks not yet identified and for active research
involving more expansive forms of causality than those imagined within the framework of
molecular biology. In describing the novelty of genome editing, such actors highlight new
processes detected in genomes and cells, and new relationships between genotype and
phenotype and between molecules within the targeted cells. Against the narrative of gene
editing as more efficient and accurate, they evoke perplexities such as unintended effects,
knowledge gaps, uncertainty, and scientific disagreement. Some call for gene technology
research in different contexts and environments of use, arguing that this research has been
tendentious in focusing more on the possibilities than on the unintended and possible
problematic effects of the use of new technologies.
These actors challenge NBAB’s differentiated assessment system based on genetic
changes in Model 1. One actor maintains that the alleged simplification of bureaucratic pro-
cesses involved in NBAB’s proposal is in fact merely a matter of simplified representation;
of not properly describing the complexity of bureaucratic processes that would be involved
in the safe assessment and possible release of GMOs into the environment also in Model 1.
Another actor points to how NBAB’s apparent lack of competence in evolutionary biology
causes it to operate with an obsolete definition of “species” and an outmoded understand-
ing precisely of what is “natural” in the transfer of genes between species. Highlighting
the agency of nature in a way that implicitly questions the biological foundation for the
differentiations of NBAB’s Model 1, this respondent is deeply concerned that NBAB’s
application of premises that lack scientific accuracy causes the entire discussion to proceed
on false grounds. Furthermore, it accuses NBAB of a one-sided, forward-looking focus that
by ignoring the complexities of naturally occurring processes of evolution can introduce
the processes of the gene technology as novel and in immediate need of harnessing.
Half of the submitted responses from this actor group suggest that NBAB’s proposal
undermines democratic processes and established relationships of trust, particularly trust in
science. One actor views the GTA’s precautionary approach as a guarantee for responsible
research and innovation (RRI). Another argues that public suspicion that new legislation is
“controlled by a power elite of selected academics and a financially strong industry with
obvious self-interests” could generate distrust in science and research institutes. These
are compelling reasons to support existing consultation processes in the GTA. Moreover,
the fear of “falling behind” should not stop inclusive and democratic involvement in the
legislative revision process. Spending time on these issues (like the EU has done) is not
necessarily a bad thing, as processes of liberalization might in retrospect be difficult (if not
impossible) to reverse.
There is division on the matter of non-safety assessment criteria among scientific
actors. The majority want non-safety assessment criteria (sustainability, societal utility,
and ethics) to remain within the GTA, but many of them agree with NBAB’s tier-based
differentiation of these criteria, as proposed in Model 1. Those in favor of maintaining them
unaltered point to the tremendous biological, bureaucratic, and democratic complexities of
gene technology research, and express the value of non-safety assessments for responsible
research. Those critical of these criteria argue that they turn the GTA into a “discriminatory”
form of legislation that hinders the development of one specific product. Some scientists
find the ability of non-safety assessments to undermine objective, scientific risk assessments
even worse than the law’s discriminatory practices. They advance claims of objectivity to
maintain non-safety evaluations as separate, purely normative evaluations that come after
or are subsumed into the more important, more objective, and somehow truer scientific
evaluations of risk. Ethical concerns are dismissed as “fuzzy” and subjective, and the
precautionary principle becomes a “status quo bias.” For such actors, the scientific and
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technological become associated with progress and development and support the greater
good for humanity. Political and ethical concern is framed as blocking this development.
3.3. The Final Proposal (D3)
In the final “Proposal for relaxation,” NBAB maintains that all GMOs should be
regulated by the GTA, allowing authorities to maintain overview and control as biotech-
nology innovations intensify in pace and scale. It nevertheless highlights the need for
differentiated regulation based on a principle of method-independent and equal treatment
of organisms with similar genetic traits. In practice, NBAB’s proposal for differentiated
regulation (Model 1) means that GMOs on level 1 (with changes that could occur naturally
or through conventional breeding methods) will be subject neither to standard risk as-
sessments nor to public hearings. NBAB’s final report strengthens the already established
framing of gene technology as a safe technology that should not be discriminated against,
for example by deleting descriptions of the randomness and unintended effects of older
forms of gene technology in its fact box on genetic engineering techniques (D3, p. 13);
by emphasizing how the impact of unintended changes varies between different kinds
of organisms and are minimized in plant breeding (D 3, p. 15); and by adding an extra
example from salmon aquaculture of how sterile salmon produced through conventional
but gene-manipulatory forms of breeding (causing triploidity) are regulated less strictly
than (seemingly healthier) gene edited salmon (D3, p. 17). The report furthermore presents
developers’ difficulties in providing documentation of the non-safety aspects of their GMO
products as arguments against non-safety assessments (D3, p. 28). In accordance with these
and similar perceived needs for legislative revision, NBAB recommends the establishment
of an official committee to review the GTA and “consider different ways of differentiating
and simplifying the processing of applications for deliberate release of GMOs” (D3, p. 4).
3.3.1. The Fate of Critical Concerns
Figure 1 gives an overview of the fate of arguments critical to NBAB’s proposed
revision of the GTA. Briefly summarized, we find that respondents’ concerns about the
effect of the proposed legislative revisions on carefully built relationships of trust (between
producers and consumers, the public and the authorities), about scientific knowledge gaps
and perplexities, about the environmental and socio-economic impact of current production
systems, and about the state of nature as a common good are in the final report treated
either in contexts in which their full impact are reduced to technical issues (trust issues
become a matter of labelling) or rendered scientifically irrelevant (scientific knowledge
gaps become a matter of ethics)—or not treated at all.
3.3.2. The Fate of Naturalness
NBAB to some extent amended the final report in response to critique about its use
of the concept of naturalness. From among the scientific and philosophical discussions of
this concept provided by respondents, they chose to include arguments about the natural
variation and transfer of genes across species and use these to claim that “mutations and
gene flow between individuals and species both occur naturally and is a driving force
for evolution. Viewed in this way, it may be problematic to classify one genetic change
produced through genetic modification as being more unnatural than another genetic
change” (D3, p. 16). Problematizing the concept of the species only to the extent that it
poses problems to the distinction between proposed regulatory tiers, NBAB re-frames an
inherently critical response in a way that naturalizes the products of gene technology while
leaving out the larger question of how its own use of the species concept [51] shapes the
debate. Nothing is mentioned of the need for competence enhancement within NBAB or
for alternative evolutionary or relational perspectives on gene technology.
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3.3.3. The Fate of Environmental Concerns
The separation of facts and values that is present in the invitational report is strength-
ened in the final report. Th claims of agricultural and environmental organizations that a
general lack knowledge of the unintended effects of gene technology necessitates a con-
tinued precautionary approach are reported in the chapter “Sustainability, societal utility
and ethics.” Facts of knowledge gaps or scientific controversies, genetic transfers, and
accumulative pressures to ecosystems in this way appear to fall in a different category
than the methods and products of the “purified” technology [48]. Unlike assessments of
health and environmental risks performed by scientists and developers of gene technology,
knowledge of actual and possible environmental effects, scientific uncertainties, and dis-
agreements emerging from other actors appears neither as directly connected to the use
and development of the technology itself nor as truly scientific.
Where concerns regarding environmental effects, scientific uncertainties, and disagree-
ments are mentioned in NBAB’s final report (D3), they are immediately neutralized by
claims of how gene technology may offer unique improvements in the sustainability of
aqua- and agricultural production chains. Indeed, the final report is somewhat confusing
because advantages of the new technologies are interwoven in discussions of challenges
and disadvantages, whereas the reverse does not occur.
3.3.4. The Fate of Ethical Assessments
The most striking difference between the invitational (D1) and the final (D3) report,
however, is that in the final report Model 2 is relegated to the appendix and no longer rep-
resented as a realistic alternative form of differentiated regulation. Two new models based
o genetic change but with fewer tiers take its place (D3, p. 41), and ethical defensibility
is entioned last and most briefly (after potential for spre ding to th vironment and
experience of use) in a new fact box listing possible further differentiations (D3, p. 42).
With this, actual criteria for the assessment of ustainability, societal utility, and ethics
both visually nd textually disappear, making it v n mor diffic lt to associate ethical
pproache with concrete cases. In the final report, the Invitation’s brief chapter entitled
“Sustainability, societal utility and e hics: How much s sufficient?” (D1, 42) is further
abbreviated and the rather telling subtitle is edited out (D3, p. 49). Out of the 60-page long
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final report (not including annexes) submitted by the NBAB to the Ministry of Climate and
Environment, a mere four-and-a-half pages deal specifically with issues of sustainability,
societal utility, and ethics.
4. Discussion
4.1. European Legislation Becomes Part of the Problem
In its 2017 “Invitation to public debate” (D1), NBAB established an economic framing
of the question of gene technology regulation that caters primarily to the interest of business
and industry actors and market-oriented scientific environments. This framing follows
quite closely what Macnaghten and Habets [11] (p. 356) identify as the “historical narrative”
used by agrochemical companies and research organizations who argue that licensing
is time consuming, expensive, and hampers innovation. NBAB chose to maintain this
framing even after the European Court of Justice on 25 July 2018 clarified the scope of the
European GMO Directive by judging that all organisms altered by mutagenesis methods
or techniques—including all products of genome editing—are subject to the Directive’s
regulations [52]. Arguably, this alleviates Norwegian actors’ concern of falling further
“out of synch” with the legislation of genome edited organisms in Europe. The fact that
NBAB makes no direct reference to this important change in its final report (D3), only
tacitly including EU legislation as part of the problem, signals its ardor to relax current
regulatory regimes.
4.2. Scientificity and “Objectivity” Promote Legislative Relaxation
NBAB appears to make room for a broad discussion on gene technology and its ethical
and societal implications in its report(s) (D1 and D3). Yet NBAB’s framing strategies,
forms of representation, and bias in favor of scientificity (the quality of being scientific)
and “objectivity” all question process-based forms of regulation and promote its model
for differentiated regulation based on genetic change. Discussions on the definition of
“the natural,” for instance, suggest—contrary to the European Court of Justice’s inter-
pretation [52]—some genome edited organisms may be considered natural and therefore
beyond the scope of the EU’s definition of GMOs. Moreover, arguments related to scientific
and technological facts appear to be included in the final Proposal (D3) to the extent that
they support legislative relaxation, downplay the unintended effects and inefficiencies of
gene technology, and promote the relative preference of new methods of genome editing
over old ones. Arguments critical to NBAB’s suggested Model 1 (D1, p. 27), for instance,
regarding the state of knowledge on which the definition of assessment categories will
depend, are not explicitly dealt with in the final report. Although this specific (and quite
fundamental) concern is voiced by all category actors, NBAB only responds by further
simplifying its model for differentiated assessment based on genetic change by reducing
the number of tiers from three to two (D3, p. 41).
4.3. Allegations of Discrimination Support Product Regulation
Given the way NBAB’s reports (D1 and D3) tacitly imply research and development
as the only sensible way forward, the resistance of several actors against non-safety as-
sessments is not surprising. Arguably, NBAB’s Invitation (D1) provides an argumentative
platform for scientists who accuse non-safety assessments of turning the GTA into a dis-
criminatory form of legislation that hinders development. Such allegations of injustice rely
on direct comparisons between individual GMO and non-GMO products. The modern
narrative of individual rights is activated on behalf of GMOs as one among many possible
category products, and the right to equal treatment under the law is associated with the
legal right of products to enter the open marketspace, not with the legal rights of living
beings selected for modification and subsequent productification. Curiously, this approach,
which is discriminatory when applied to GMOs, is in turn used on gene modifying tech-
niques characterized as conventional to set them apart from the new genome editing
technologies. This reveals how the concept of GMOs in the discourse on gene technology
Sustainability 2021, 13, 7643 18 of 25
becomes differentiated or not according to context, discursive positioning [53], and, in
NBAB’s reports, in accordance with a felt need for more product-based approaches and a
subsequent relaxation of current regulation.
NBAB aims for a re-definition of GMOs and a revision of current legislation towards
a product-based regulation inspired by North American regulatory frameworks. Within
such frameworks, science is given great defining power over further innovation and is
regarded as the carrier of progress and humanitarian endeavors cf. [32], and governmental
control over legislation is understood to obstruct or render impossible such endeavors [27].
Despite several respondents’ dismissal of “the ethical” model for regulation, the hearing
reveals that this interpretation of the government’s role in innovation is foreign to many
Norwegians. This is particularly the case for environmental and agricultural organizations
who consider it the task of Norwegian government and legislation to protect the health of
Norwegian ecosystems, the culturally deep-founded status of nature as a common good,
and the uniqueness and market value of already existing products of agri- and aquaculture
(See Table 1).
4.4. Fact–Value Distinctions Minimize the Role of Ethics
NBAB’s two reports (D1 and D3) appear to reinforce existing and problematic divisions
between scientific facts and societal, political, and ethical values, and assign more power
to techno-scientific environments over the development and use of gene technology. Fact–
value distinctions seem to determine the strategic inclusion and treatment of respondents’
arguments and concerns in the final report (D3), but in this connection, legal and economic
concerns are treated like facts. Economic concerns constitute the major framing of issues
under discussion, and respondents’ critique concerning the legal repercussions of the
presented regulatory revisions are met by adding an extra chapter to the final report on
“Flexibility under current regulations” (D3, p. 50).
NBAB could have chosen to address concerns expressed by agricultural and environ-
mental organizations and many scientific environments by explaining ethical frameworks
in more detail and relating them to practices in laboratories and in agri- or aquaculture
production lines. Instead, its final report (D3) sidelines ethical problems and discussions
along with its ethical Model 2 (D1, p. 34). This makes it even more difficult to associate
ethical approaches with concrete cases and edits out the idea of political/ethical control
over the direction of technological development. As scientific processes are “purified”
and kept separate from ethical questions, concerns regarding the under-communication of
perplexities or research focusing more on the possibilities than on the possible problem-
atic effects of the new technologies find no grounds for support—even when posed from
within scientific communities (D2). Such ethical considerations remain suspended above
discussions of the scientific details of the new technologies under development and become
only vaguely expressed in respondents’ calls for more—and more independent—research.
NBAB’s discussion of the ethical and societal concerns remain vague and abstract, except
when in favor of new GMOs, thereby restricting open and frank debate.
4.5. A Latourean Framework Highlights Gaps between Mandate and Practice
What makes this negligent treatment of ethical questions both curious and problematic
is the complexity of NBAB’s mandate and function. In addition to providing advice on
matters concerning the use of biotechnology, NBAB is given special responsibility for the
processes of consultation: making sure all voices are heard and all matters of concern
are aired in the complex decision-making on whether and how to include GMOs in the
Norwegian collective (D1, p. 2). In Latourean terms, NBAB thus performs a political
function with great potential to broaden knowledge construction. However, with its
officially assigned role in providing the government with recommendations on the non-
safety aspects of GMO applications, NBAB is also the designated philosopher/moralist of
the Norwegian regulatory system. This role is not made clear in either report (D1 or D3).
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In Latour’s model for political ecology, philosophers/moralists serve two important
functions. One is to evaluate and place into one common hierarchy the different values
and matters of concern expressed within the collective. The other function, significant to
our analysis, is to constantly question the status quo, thereby allowing new (or previously
rejected) natural–cultural entities to (again) be considered candidates for possible member-
ship in the good, common world [28] (pp. 156–158). Philosophers/moralists are thus—like
scientists evoking perplexity—important in involving the political–ecological collective in
constant and iterative trials for inclusion. However, in order for this recursivity to have
a purpose, consultations must proceed and be recorded fairly. According to Latour, the
procedural expertise of administrators/bureaucrats is what prevents “all the powers, all
the partial competencies, from interrupting the exploration of the learning curve, or from
dictating its results in advance” [28] (p. 206). In this manner, responsibility for the ethical
foundation for discussion within the collective is shared between philosophers/moralists,
scientists, politicians, and administrators/bureaucrats.
Through its “Invitation to public debate” (D1), NBAB aims to fulfill its political
responsibility to bring out a broad array of relevant voices and witnesses to debate what
GMOs are and could become, and how they may come to impact the collective. NBAB
brings the case of genome editing before the decision-making processes of the collective
on the argument that their characteristics have changed in fundamental ways. As such, it
performs well the philosopher/moralist’s task of keeping the political-ecological collective
in an open and ongoing process of composition, albeit in a manner that seems particularly
sensitive to the competitive needs of gene technology science and industry. (Noteworthy
in this respect is that unlike scientists within other environmental sciences—for which
Latour developed his model—geneticists and molecular scientists not only identify, but also
engender and may come to significantly benefit from the candidates for common existence
which they propose as members of the common collective.) What we find problematic
is the way NBAB maintains a strict separation of facts and values that hampers a proper
discussion and ranking of values. By allowing the fact-value distinction and molecular
biology’s “safe enough” framing to limit the contribution of other forms of knowledge in
the construction of the facts of gene technology, these other forms of knowledge remain
irrelevant to definitions of the state of the world on which value discussions on gene
technology proceed. In NBAB’s report(s), this applies whether the knowledge in question
concerns the actual (technical) application of new gene technologies in the lab or the state
of the (natural) world outside it.
On the bases of the many framing strategies applied in the presentation of “the prob-
lem” of GMO regulation, NBAB appears to perform poorly its responsibility to engender
an open, inclusive, and transparent form of consultation in which different actors partici-
pate on equal terms. Our Latourean perspective reveals this to be an epistemological as
well as a democratic problem. In the final report (D3), NBAB’s emphasis on narratives of
techno-scientific development favors respondents with the narrowest sense of what consti-
tutes proper consultation on gene technology. In so doing, it neglects perspectives from
respondents with more complex and inclusive understandings of the common world and
the place of GMOs within it. This is unfortunate, as a recent Norwegian survey revealed
positive attitudes toward genome editing technologies if they promoted sustainability,
promised societal benefits, did not negatively impact animal welfare, and if they were
developed, used, and regulated in Norway [14]. A high level of trust in the ethical sound-
ness of both the production and the regulation of GMOs seems thus vital to Norwegian
consumers’ acceptability of new gene technologies. Accordingly, careful deliberations on
the non-safety aspects of the use of these technologies must be performed to prevent their
introduction from happening at the expense of the public’s trust in Norwegian producers
and authorities.
NBAB frames a change in the GTA as a matter of regulatory practice. It engages
primarily in issues believed to make the practical part of regulatory assessments easier
and more predictable for developers. Yet it also leaves aside proper discussions of concern
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for the integrity of living beings, single and accumulative effects on ecosystems, current
practices of industrialized aqua- and agriculture, and nature–culture relationships. In doing
so, it treats the associated radical uncertainties negligently and lets the discussion proceed
comfortably and uncritically within the framework of current science policy culture. Fur-
thermore, NBAB fails to seriously open up to broader forms of knowledge construction and
cross-disciplinary collaborations capable of addressing more complex forms of scientific,
ecological, and cultural perplexities. NBAB’s suggestion is for a regulatory system that
is rigged to treat GMOs not as individual and exceptional applicants to membership in
the collective, but as already accepted members for whom we need practical procedures
for speedy inclusion, accommodation, and (hopefully) monitoring. NBAB notes, but does
not seriously consider, the fact that agricultural and environmental organizations find the
combination of regulatory and technological efficiency threatening in itself. There is no
room for a critique of the system in NBAB’s report(s).
NBAB’s report(s) have elements of what Jasanoff et al. have described as “chore-
ographed conversations on issues experts have predetermined to warrant debate” in which
“speaking the right language, that of scientific rationality,” is necessary in order to engage
in deliberative democracy [29] (p. 32). As a small milk farmer’s cooperative perceptively
pointed out in its hearing response, NBAB’s report creates the sense that “being against the
use of gene technology is not an option.” Through some very subtle use of rhetoric and
forms of representation, the basis for such alternative and critical value-based evaluations
has been rendered negligible to the extent that their expression becomes almost impossible.
4.6. GMOs at the Heart of Political and Value-Laden Projects to Construct a Good Common World
Latour’s model for political ecology provides a suitable lens through which to analyze
current debates on GMOs and their regulation. The model’s central premise is that all such
deliberative processes are part of the political and value-laden project of constructing a good
common world: one in which techno-scientific developments do not return at later stages
and in surprising ways to disrupt the collective sense of comfort and safety. It reworks
the idea of ethics and redistributes responsibility for it beyond ethicists: to scientists and
their recognition of perplexity, politicians who must ensure proper consultation among
new actors and reliable witnesses, and administrators/bureaucrats who musts perform
truthful and accurate recordings of deliberations performed and decisions made. Vice versa,
the idea of knowledge production is reworked to include questions of consultation and
ethics. Latour’s model outlines new and broader forms of co-construction of knowledge
and value negotiation that may help long-standing efforts to democratize predominantly
science-based consultations on gene technology. This is especially important in debates
where government-appointed actors like NBAB employ discursive framings to de-politicize
technology in contrast to NGOs’ aim to politicize it [30].
Where current forms of knowledge production reach their limits is where we must
acknowledge perplexity. By allowing us to distinguish between complexities—that which,
through careful and holistic research approaches, may be resolved, and perplexities—that
which lies beyond the scope of current knowledge-production systems—Latour’s model
for political ecology facilitates a concretization of public concern for perplexities (or at least
provides a category in which to place and account for such concerns). Integrating these in
the consultation processes seems precisely to be the aim of agricultural and environmental
organizations who value current production systems (traditional as well as ecological)
and ecosystem services whose full magnitude of complexity/interaction tend to remain
undetected until contaminated or broken [54]. Their call to maintain the democratic
processes involved in the current regulation on GMO applications can be read as a call to
allow openness to perplexity to remain, to allow processes of consultation to take as much
time and include as many propositions and voices as possible. Accordingly, it is important
that these voices not be silenced—particularly by governmental bodies officially assigned
the role of ensuring proper consultations on gene technology.
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5. Conclusions
NBAB claims that gene technology will become an important and enabling technology
within the emerging bioeconomy. In order to achieve this goal without significantly upset-
ting existing value systems, there is a profound need to reconsider the kind of knowledge
production needed to engender proper and equitable processes of deliberation. We believe
such knowledge production must not only be open about scientific and environmental per-
plexities involved in the development and use of new gene technologies, but also involve a
broader range of actors from beyond the (molecular) sciences. Only through more inclusive
deliberations that transcend ingrained fact–value/science–ethics distinctions and encom-
pass nonhuman biological and/or ecological parts of the nature–culture collective can the
new gene technologies fulfil the visions of sustainability that their proponents present.
Our case study demonstrates how poststructuralist discourse analysis inspired by
Latour’s model for political economy can be useful in gauging the openness of processes of
consultation and seeking better and broader problem formulations in matters concerning
the regulation and use of new gene technologies. Although focused on one specific and
time-limited instance of public debate in Norway, a country known for its unique inclusion
of non-safety considerations in GMO regulation, our study reveals a general need to
consider the processes involved in public debates on gene technology in their entirety.
Only thus will it be possible to detect the manner and extent to which discursive framings,
selective emphasis on desired lines of argumentation, and partial reporting hinder fair and
proper consultation and render engagement futile for certain actors.
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Appendix A
Table A1. Source data for discourse analysis.
Data
Category Kind of Document Document: Document Length (in p)
D1 Hearing invitation
Norwegian Biotechnology Advisory Board:
The Gene Technology Act—Invitation to Public Debate [22] 52
(Genteknologiloven—Invitasjon til offentlig debatt [24]) (52)
D2 Hearing responses
Norwegian Biotechnology Advisory Board:
Mottatte innspill (Replies received) [42]
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Table A1. Cont.
Data
Category Kind of Document Document: Document Length (in p)
Umbrella
organizations (10)
Sjømat Norge (Seafood Norway) 4
NHO Mat og Drikke (FoodDrinkNorway) 4
Norsk Industri (The Federation of Norwegian Industry CNE) 1
Legemiddelindustrien (The Medical Industry) 3
Statens Legemiddelverk (The Norwegian Medicines Agency) 4
Tekna (The Norwegian Society of Graduate Technical and
Scientific Professionals) 5




Nettverk for GMO-fri Mat og Fôr (Network for GMO-free
foods and animal feed) 6
Organizations (7)
Norges Bondelag (Norwegian Farmers’ Association) 2
Norsk Bonde- og Småbrukarlag (Norwegian Farmers’ and
Smallholders’ Association) 2
Økologisk Norge (Oikos—Organic Norway) 3
Bondens marked Norge (Farmer’s Market Norway) 3
Norges Bygdekvinnelag (Norway’s Rural
Women’s Association) 3
Norges Naturvernforbund (Norwegian Society for the
Conservation of Nature) 4









ACD Pharmaceuticals AS 2
Fakultet for Biovitenskap, NMBU (Faculty of Biosciences,
Norwegian University of Life Sciences) 3
Institutt for Naturhistorie, NTNU (NTNU University
Museum’s Department of Natural History, Norwegian
University of Science and Technology)
3
Havforskningsintituttet (Institute of Marine Research) 2
Genøk— Senter for biosikkerhet (GenØk—Center for Biosafety) 13
Institutt for biovitenskap, UiB (Department of Biological
Sciences, University of Bergen) 4
Nofima 2
UiO (University of Oslo) 5
13 researchers NMBU/NIBIO/UiO 3
Dorothy Dankel 1
Audun Nerland 12
Camilla H. Jensen og Åsmund Kaupang 7
Thomas Tichelkamp 3
Other institutions (4)
Landbruksdirektoratet (Norwegian Agriculture Agency) 1
Kirkerådet (Church of Norway) 5
NENT (National Committee for Research Ethics in Science
and Technology) 3
Ryggvold Melkeproduksjon (Ryggvold Milk Production) 1
Other individual responses (8)
Liv Langberg 4
Øyvind Nilsen 1
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Table A1. Cont.
Data
Category Kind of Document Document: Document Length (in p)
D3 Hearing report
Norwegian Biotechnology Advisory Board:
Proposal for relaxation of Norwegian regulations for deliberate
release of genetically
modified organisms (GMO), with applicability also for EU
legislation [25] 66
(Forslag til oppmykning av regelverket for utsetting av
genmodifiserte organismer [43]) (63)
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